CSL reflects on its future, past as new R&D lab opens

Last month, global pharmaceutical maker CSL cut the ribbon on a brand-new research facility in Waltham, Massachusetts, where the company will focus on vaccine research, including next-generation mRNA products and work that will go on in an ultra high-security BSL3 lab.

pharmaphorum's editor-in-chief, Jonah Comstock, attended the festivities and, whilst at the facility, was able to sit down with Bill Mezzanotte, head of R&D and chief medical officer at CSL, together with Dr Paul McKenzie, CSL’s brand new CEO (officially having stepped up in March).

In this series of on-site sit-downs, Mezzanotte and McKenzie talk about why they’ve chosen this moment to open a new research facility, some of their plans for the space, and how this facility fits into CSL’s long and storied history in infectious disease research. They also get into the benefits of the Waltham area and a little about the company’s plans in cell and gene therapy.